1. Home
  2. MXCT vs ABEO Comparison

MXCT vs ABEO Comparison

Compare MXCT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MXCT
  • ABEO
  • Stock Information
  • Founded
  • MXCT 1999
  • ABEO N/A
  • Country
  • MXCT United States
  • ABEO United States
  • Employees
  • MXCT N/A
  • ABEO N/A
  • Industry
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ABEO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MXCT Health Care
  • ABEO Health Care
  • Exchange
  • MXCT Nasdaq
  • ABEO Nasdaq
  • Market Cap
  • MXCT 275.7M
  • ABEO 237.4M
  • IPO Year
  • MXCT 2021
  • ABEO 1980
  • Fundamental
  • Price
  • MXCT $2.73
  • ABEO $5.28
  • Analyst Decision
  • MXCT Strong Buy
  • ABEO Strong Buy
  • Analyst Count
  • MXCT 2
  • ABEO 5
  • Target Price
  • MXCT $10.00
  • ABEO $17.00
  • AVG Volume (30 Days)
  • MXCT 621.3K
  • ABEO 872.6K
  • Earning Date
  • MXCT 05-07-2025
  • ABEO 05-14-2025
  • Dividend Yield
  • MXCT N/A
  • ABEO N/A
  • EPS Growth
  • MXCT N/A
  • ABEO N/A
  • EPS
  • MXCT N/A
  • ABEO N/A
  • Revenue
  • MXCT $38,627,000.00
  • ABEO N/A
  • Revenue This Year
  • MXCT $9.05
  • ABEO N/A
  • Revenue Next Year
  • MXCT $19.98
  • ABEO $539.93
  • P/E Ratio
  • MXCT N/A
  • ABEO N/A
  • Revenue Growth
  • MXCT N/A
  • ABEO N/A
  • 52 Week Low
  • MXCT $2.21
  • ABEO $3.05
  • 52 Week High
  • MXCT $5.26
  • ABEO $7.73
  • Technical
  • Relative Strength Index (RSI)
  • MXCT 47.09
  • ABEO 59.10
  • Support Level
  • MXCT $2.29
  • ABEO $4.66
  • Resistance Level
  • MXCT $2.74
  • ABEO $5.02
  • Average True Range (ATR)
  • MXCT 0.24
  • ABEO 0.42
  • MACD
  • MXCT 0.06
  • ABEO 0.09
  • Stochastic Oscillator
  • MXCT 88.14
  • ABEO 97.47

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Share on Social Networks: